同步放化疗联合靶向治疗中晚期非小细胞肺癌疗效观察

Efficacy of concurrent chemoradiotherapy combined with targeted therapy for advanced non-small cell lung cancer

目的探讨中晚期非小细胞肺癌行同步放化疗联合靶向治疗的临床效果。方法选取2014年1月至2016年1月间泰州市第二人民医院收治的54例中晚期非小细胞肺癌患者,采用随机数表法分为观察组与对照组,每组27例,观察组患者采用同步放化疗联合靶向治疗,对照组患者采用单纯同步放化疗治疗,比较两组患者的功能状态(KPS)评分、治疗效果、不良反应及生活质量。结果治疗后,两组患者KPS评分与治疗前比较均明显升高,且观察组患者评分高于对照组,差异均有统计学意义(均P<0.05)。观察组患者治疗总有效率为81.5%,对照组为63.0%,两组比较,差异有统计学意义(P<0.05)。治疗过程中,观察组患者胃肠道反应和骨髓抑制发生率分别为14.8%和7.4%,均显著低于对照组的33.3%和55.6%,差异均有统计学意义(均P<0.05)。治疗后,观察组患者生活质量各项指标均显著高于对照组,两组比较,差异均有统计学意义(均P<0.05)。结论中晚期非小细胞肺癌行同步放化疗与靶向联合治疗效果显著,不良反应少,可提高患者生活质量。

Objective To explore the efficacy of concurrent chemoradiotherapy combined with targeted therapy for advanced non-small cell lung cancer（ NSCLC）. Methods Fifty-four NSCLC patients treated at Taizhou Second People＇s Hospital between January 2014 and January 2016 were selected and randomly divided into an observation group and a control group using a random number table with 27 each. The observation group was given concurrent chemoradiotherapy combined with targeted therapy and the control group was only given concurrent chemoradiotherapy. Karnofsky performance score（ KPS）,efficacy of treatment,adverse reactions and quality of life were compared between the tow groups. Results After the treatment,KPS significantly improved in both groups compared with before the treatment with the improvement higher in the observation group than in the control group（ all P〈0. 05）. The overall efficacy rate was 81. 5% for the observation group and 63. 0% for the control group（ P〈0. 05）. The incidence of gastrointestinal reactions and bone marrow suppression were 14. 8% and 7. 4% in the observation group,respectively,which were significantly lower than 33. 3% and 55. 6% of the control group,respectively（ all P〈0. 05）. After the treatment,the scores of quality of life were significantly higher in the observation group than in the control group（ all P〈0. 05）. Conclusion The concurrent chemoradiotherapy combined with targeted therapy in the treatment of advanced NSCLC shows high efficacy with few adverse reactions and high quality of life.